TABLE 3

Bivariate and multivariate analyses: baseline anticoagulant users versus nonusers

	Bivariate analyses		Multivariate analyses
	Hazard ratio (95% CI)	p-value	Hazard ratio (95% CI)	p-value
Disease progression^#	1.2 (0.7–2.1)	0.435	1.2 (0.6–2.6)	0.600
Mortality
All-cause mortality	2.7 (1.1–6.9)	0.037	2.6 (0.7–8.8)	0.136
IPF-related mortality	4.4 (1.7–11.5)	0.003	4.7 (1.1–19.3)	0.034
FVC change
Absolute decrease ≥5%	1.3 (0.8–2.2)	0.284	1.2 (0.6–2.6)	0.578
Relative decrease ≥5%	1.1 (0.7–1.8)	0.773	1.0 (0.5–1.9)	0.936
Absolute decrease ≥10%	1.2 (0.5–2.6)	0.736	1.6 (0.5–5.3)	0.438
Relative decrease ≥10%	1.3 (0.7–2.4)	0.370	1.2 (0.5–2.9)	0.743
Death or FVC (absolute) ≥10% decrease	1.6 (1.0–2.8)	0.065	1.5 (0.7–3.3)	0.316
Death or 6MWD decrease ≥50 m	1.2 (0.7–2.1)	0.528	1.2 (0.5–2.5)	0.701
All-cause hospitalisation	1.2 (0.6–2.7)	0.581	1.2 (0.4–3.2)	0.766

IPF: idiopathic pulmonary fibrosis; FVC: forced vital capacity; 6MWD: 6-min walk distance. ^#: defined as ≥10% decrease in FVC % pred, ≥50 m decline in 6MWD or death.